Filana Therapeutics, Inc. (FLNA)
NASDAQ: FLNA · Real-Time Price · USD
1.690
+0.070 (4.32%)
At close: Mar 31, 2026, 4:00 PM EDT
1.700
+0.010 (0.59%)
After-hours: Mar 31, 2026, 7:23 PM EDT
Filana Therapeutics Employees
As of December 31, 2025, Filana Therapeutics had 20 total employees, including 17 full-time and 3 part-time employees. The number of employees decreased by 10 or -33.33% compared to the previous year.
Employees
20
Change (1Y)
-10
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$4,548,650
Market Cap
81.64M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 20 | -10 | -33.33% | 17 | 3 |
| Dec 31, 2024 | 30 | 1 | 3.45% | 30 | 0 |
| Dec 31, 2023 | 29 | 3 | 11.54% | 29 | 0 |
| Dec 31, 2022 | 26 | 2 | 8.33% | 26 | 0 |
| Dec 31, 2021 | 24 | 13 | 118.18% | 24 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Champions Oncology | 213 |
| PolyPid | 73 |
| Seres Therapeutics | 66 |
| Pliant Therapeutics | 49 |
| Aardvark Therapeutics | 40 |
| Vivani Medical | 37 |
| Gain Therapeutics | 25 |
| NeurAxis | 21 |
FLNA News
- 5 weeks ago - Cassava Sciences says US DOJ has closed investigation into company - Reuters
- 3 months ago - HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - PRNewsWire
- 3 months ago - FDA Puts Cassava's Simufilam Epilepsy Trial On Full Clinical Hold - Benzinga
- 5 months ago - Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
- 5 months ago - Cassava Sciences Appoints Dawn C. Bir to the Board of Directors - GlobeNewsWire
- 8 months ago - Cassava Reports Q2 2025 Financials Results and Provides Business Update - GlobeNewsWire
- 8 months ago - Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer - GlobeNewsWire
- 8 months ago - Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy - GlobeNewsWire